FDA accelerates psychedelic drug research

President Donald Trump has signed an executive order directing the U.S. Food and Drug Administration to accelerate research and development of psychedelic treatments for serious mental illnesses. The order aims to fast-track clinical trials and regulatory pathways for substances like psilocybin and MDMA, which are being studied for conditions such as PTSD and depression. This move represents a significant shift in federal drug policy and could lead to new FDA-approved therapies within the next few years.